Clinical Trial Update: Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a three-drug combination of azacitidine, venetoclax, and trametinib for relapsed or refractory acute myeloid leukemia or higher-risk my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• MEKINIST (trametinib)
• VIDAZA (AZACITIDINE)
• Venclyxto (Venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2025-04-22